Why Is Alumis Inc. (ALMS) Stock Down -53.14% Today?
Key Takeaways
- ALMS shares plunged roughly 53% after the company reported that its Phase 2b LUMUS trial of envudeucitinib in systemic lupus erythematosus (SLE) missed its primary and secondary endpoints in the overall patient population.
- The late-stage readout failure on the lead lupus program overshadowed encouraging efficacy in a predefined subgroup of patients with a high interferon gene signature (IFNGS-high).
- Management reiterated it remains on track to submit a New Drug Application (NDA) for envudeucitinib in moderate-to-severe plaque psoriasis in the fourth quarter of 2026.
- Trading volume surged well above the daily average, signaling heavy repositioning by investors.
- The selloff was company-specific, diverging from the broader biotech and equity benchmarks.
- Traders are now watching the psoriasis NDA filing, potential Phase 3 lupus discussions with regulators, and the company's capital position.
Opening Summary
Alumis Inc. (ALMS), a South San Francisco-based late-stage biopharmaceutical company developing oral tyrosine kinase 2 (TYK2) inhibitors for immune-mediated diseases, saw its shares plummet in Tuesday's session after a disappointing clinical readout. The stock traded around $10.22 in early trading, down about 53% from Monday's closing price of $21.81. The move was driven almost entirely by the company's announcement that its Phase 2b LUMUS trial of envudeucitinib for moderate-to-severe systemic lupus erythematosus did not achieve its primary or secondary endpoints across the full study population.
Phase 2b LUMUS Trial Misses Primary Endpoints
The dominant catalyst behind the price decline was the topline failure of the LUMUS study. The global, randomized, double-blind, placebo-controlled Phase 2b trial enrolled 408 adults with moderately-to-severely active, autoantibody-positive SLE and evaluated multiple doses of envudeucitinib against placebo over 48 weeks. The primary endpoint, measured by the BICLA composite assessment of disease activity at Week 48, was not met in the overall trial population, and key secondary endpoints also failed to reach statistical significance.
Because envudeucitinib represents a central asset in Alumis's pipeline, the miss prompted a sharp repricing of the shares. Clinical-stage biotech valuations are heavily tied to the probability of late-stage success, and a failure in a lead indication can remove a meaningful portion of a company's expected future value in a single session.
A Mixed Readout: IFNGS-High Subgroup and the Psoriasis Program
Not all of the data was negative. The company reported robust clinical responses in a prespecified subgroup of patients with a high interferon gene signature, including on the primary endpoint and several secondary measures. Alumis attributed the overall miss partly to the fact that IFNGS-high patients — who typically respond better to interferon-pathway-targeted therapies — were unexpectedly under-represented in the trial. Management said it plans to engage regulators to discuss Phase 3 development in SLE based on this subgroup.
The safety profile was also reassuring: envudeucitinib was generally well tolerated with no new safety signals. Crucially, the company reaffirmed that its Phase 3 ONWARD program in moderate-to-severe plaque psoriasis produced positive results and that it remains on track to file an NDA in the fourth quarter of 2026. This psoriasis program gives ALMS a nearer-term regulatory catalyst that partially offsets the lupus setback, though investors on Tuesday focused squarely on the headline failure.
Market Context and Trading Activity
The plunge was driven by company-specific news rather than broad market weakness. Trading volume climbed sharply relative to recent sessions as investors reassessed the risk profile of the pipeline. The move broke well below the stock's recent trading range, and the shares surrendered a large portion of the gains built up earlier in the year, underscoring the binary, event-driven nature of biotech investing. The stock's 52-week range spans roughly $3.76 to $31.35, reflecting the extreme volatility that has characterized the name since its 2024 listing.
What Comes Next for ALMS
Investor attention now shifts to several upcoming catalysts. Near term, the market will watch for details on the psoriasis NDA submission expected in the fourth quarter of 2026 and any regulatory feedback on a potential Phase 3 lupus program guided by the IFNGS-high subgroup. Management has also signaled it is evaluating opportunities to maximize the value of its oral TYK2 portfolio, which includes the CNS-penetrant asset A-005 for neuroinflammatory and neurodegenerative diseases. Analysts remain largely constructive on the stock, though the lupus setback raises questions about the company's broader pipeline strategy, capital runway, and execution risk across remaining indications.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots that have demonstrated the strongest performance under current market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, with each bot differing by strategy, timeframe, performance metrics, and the symbols it trades. Explore the page to discover the AI strategies currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
ALMS in -2.14% downward trend, declining for three consecutive days on September 18, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ALMS declined for three days, in 123 of 139 cases, the price declined further within the following month. The odds of a continued downward trend are 88%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day moving average for ALMS crossed bearishly below the 50-day moving average on August 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 4 of 5 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for ALMS entered a downward trend on September 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 13 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 15 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +19.96% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALMS advanced for three days, in 100 of 128 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
ALMS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 40 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.224) is normal, around the industry mean (25.951). P/E Ratio (0.166) is within average values for comparable stocks, (40.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.265). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (123.457) is also within normal values, averaging (436.793).
The Tickeron Price Growth Rating for this company is 66 (best 1 - 100 worst), indicating fairly steady price growth. ALMS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALMS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement